Page last updated: 2024-08-24

aromasil and Bone Loss, Perimenopausal

aromasil has been researched along with Bone Loss, Perimenopausal in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ali, SM; Budd, GT; Chapman, JW; Elliott, CR; Ellis, MJ; Garg, A; Goss, PE; Han, L; Ingle, JN; Leitzel, K; Lipton, A; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW	1
Tang, SC	1
Esteva, FJ; Hortobagyi, GN	1
Chien, AJ; Goss, PE	1

Reviews

3 review(s) available for aromasil and Bone Loss, Perimenopausal

Article	Year
Women and bone health: maximizing the benefits of aromatase inhibitor therapy. Oncology, 2010, Volume: 79, Issue:1-2 Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Colorectal Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; RANK Ligand; Secondary Prevention; Tamoxifen; Triazoles; Zoledronic Acid	2010
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast (Edinburgh, Scotland), 2006, Volume: 15, Issue:3 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Risk Factors; Tamoxifen; Triazoles; Triglycerides	2006
Aromatase inhibitors and bone health in women with breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-20, Volume: 24, Issue:33 Topics: Absorptiometry, Photon; Algorithms; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Remodeling; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Life Style; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Population Surveillance; Risk Factors; Triazoles	2006

Trials

1 trial(s) available for aromasil and Bone Loss, Perimenopausal

Article	Year
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27. Cancer, 2017, Jul-01, Volume: 123, Issue:13 Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Male; Mastectomy; Middle Aged; Multivariate Analysis; Nitriles; Osteoporosis, Postmenopausal; Proportional Hazards Models; Radiotherapy, Adjuvant; Receptors, Estrogen; Treatment Outcome; Triazoles	2017

Article

Year

Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.

Cancer, 2017, Jul-01, Volume: 123, Issue:13

Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Male; Mastectomy; Middle Aged; Multivariate Analysis; Nitriles; Osteoporosis, Postmenopausal; Proportional Hazards Models; Radiotherapy, Adjuvant; Receptors, Estrogen; Treatment Outcome; Triazoles

2017